Methods comprising apoptosis inhibitors for the generation of transgenic pigs |
 |
|
|
||||||||||||||||||||||||||||||||||||||||||
| Title: | Transgenic mouse having a disrupted amyloid precursor protein gene |
| Inventors: | Zheng, Hui; Rahway, NJ, USA Chen, Howard Y.; Rahway, NJ, USA Trumbauer, Myrna E.; Rahway, NJ, USA van der Ploeg, Leonardus H. T.; Rahway, NJ, USA Seabrook, Guy; Harlow, United Kingdom Sirinathsinghji, Dalip; Harlow, United Kingdom |
| Summary: | This invention describes a transgenic mouse comprising a genomic disruption which produces no functional amyloid precursor protein as a result of this gene disruption. Described herein are specific methods of producing a transgenic nonhuman animal lacking native amyloid precursor protein as a result of a genome which contains a disruption of the gene encoding amyloid precursor protein (APP), such that functional APP is not produced. The mouse thus exhibits a phenotype selected from impaired long-term potentiation, a decrease in presynaptic markers, a decrease in dendritic marker MAP-2 in the cortex, an increase of dendritic marker MAP-2 in CA1 pyramidal cells in the hippocampus, and/or weight loss as compared to a wild-type mice. Such a transgenic mouse model may be useful in the study of Alzheimer's Disease and disorders involving the central nervous system. |
| Abstract: | The present invention relates to a transgenic nonhuman animal lacking native amyloid precursor protein. The transgenic mouse of the invention may be used in the study of Alzheimer's Disease and disorders involving the central nervous system. |
| US Patent Website: | Click Here for Full Text of Patent |
| Title Number: | US6187992 |
| Application Number: | US1999000266475 |
| Date Filed: | 11/03/1999 |
| Date Published: | 13/02/2001 |
| Assignee: | Merck and co., Inc., Rahway, NJ, USA Merck Frosst Canada and Co., Kirkland, Canada |